<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460274</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1107</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101107</ELocationID><Abstract><AbstractText Label="BACKGROUND/OBJECTIVES" NlmCategory="OBJECTIVE">This retrospective cohort study evaluated the relative vaccine effectiveness (rVE) of two bivalent (original/Omicron BA.4/BA.5) vaccines mRNA-1273.222 versus the BNT162b2 Bivalent in preventing COVID-19-related outcomes in adults with underlying medical conditions associated with increased risk for severe COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a linked electronic health record/claims dataset, US adults (≥18 years) with ≥1 underlying medical condition of interest who received either the bivalent vaccine between 31 August 2022 and 28 February 2023 were identified. The inverse probability of treatment weighting was used to adjust for cohort differences. Cohorts were followed up for COVID-19-related hospitalizations and outpatient encounters until 31 May 2023. Hazard ratios and rVEs were estimated using Cox regression. Subgroup analyses were performed on individuals with pre-specified comorbid conditions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">757,572 mRNA-1273.222 and 1,204,975 BNT162b2 Bivalent recipients were identified. The adjusted rVE over a median follow-up of 198 days was 10.9% (6.2%-15.2%) against COVID-19-related hospitalization and 3.2% (1.7%-4.7%) against COVID-19-related outpatient encounters. rVE estimates for COVID-19 hospitalizations among subgroups with comorbid conditions were as follows: diabetes 15.1% (8.7%-21.0%), cerebro- and cardiovascular disease 14.7% (9.0%-20.1%), chronic lung disease 11.9% (5.1%-18.2%), immunocompromised 15.0% (7.2%-22.2%), chronic kidney disease 8.4% (0.5%-15.7%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Overall, among adults with underlying medical conditions, mRNA-1273.222 was more effective than BNT162b2 Bivalent, especially in preventing COVID-19-related hospitalizations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kopel</LastName><ForeName>Hagit</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Van Hung</ForeName><Initials>VH</Initials><AffiliationInfo><Affiliation>VHN Consulting Inc., Montreal, QC H2V 3L8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogdanov</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Veradigm, Chicago, IL 60654, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winer</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Veradigm, Chicago, IL 60654, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boileau</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>VHN Consulting Inc., Montreal, QC H2V 3L8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ducruet</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>VHN Consulting Inc., Montreal, QC H2V 3L8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Ni</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Veradigm, Chicago, IL 60654, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winer-Jones</LastName><ForeName>Jessamine P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0002-6412-4139</Identifier><AffiliationInfo><Affiliation>Veradigm, Chicago, IL 60654, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esposito</LastName><ForeName>Daina B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bausch-Jurken</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck</LastName><ForeName>Ekkehard</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2022-9190</Identifier><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonafede</LastName><ForeName>Machaon</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Veradigm, Chicago, IL 60654, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansi</LastName><ForeName>James A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0001-7650-6778</Identifier><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N/A</GrantID><Agency>Moderna Therapeutics (United States)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BNT162b2</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">comorbidities</Keyword><Keyword MajorTopicYN="N">high risk</Keyword><Keyword MajorTopicYN="N">mRNA-1273</Keyword><Keyword MajorTopicYN="N">rVE</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>H.K., D.B.E., M.B.-J., E.B. and J.A.M. are employees of and shareholders in Moderna Inc. A.B., J.P.W.-J., N.Z., I.W. and M.B. are employees of Veradigm, which was contracted by Moderna and received fees for data management and statistical analyses. V.H.N., C.B. and T.D. are employees of VHN Consulting, which was contracted by Moderna to help conduct this analysis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460274</ArticleId><ArticleId IdType="pmc">PMC11511346</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101107</ArticleId><ArticleId IdType="pii">vaccines12101107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lythgoe K.A., Golubchik T., Hall M., House T., Cahuantzi R., MacIntyre-Cockett G., Fryer H., Thomson L., Nurtay A., Ghafani M., et al. Lineage Replacement and Evolution Captured by 3 Years of the United Kingdom Coronavirus (COVID-19) Infection Survey. Proc. Biol. Sci. 2023;290:20231284. doi: 10.1098/rspb.2023.1284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rspb.2023.1284</ArticleId><ArticleId IdType="pmc">PMC10581763</ArticleId><ArticleId IdType="pubmed">37848057</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S., Bhattacharya M., Nag S., Dhama K., Chakraborty C. A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies. Viruses. 2023;15:167. doi: 10.3390/v15010167.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15010167</ArticleId><ArticleId IdType="pmc">PMC9866114</ArticleId><ArticleId IdType="pubmed">36680207</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian D., Sun Y., Xu H., Ye Q. The Emergence and Epidemic Characteristics of the Highly Mutated SARS-CoV-2 Omicron Variant. J. Med. Virol. 2022;94:2376–2383. doi: 10.1002/jmv.27643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27643</ArticleId><ArticleId IdType="pmc">PMC9015498</ArticleId><ArticleId IdType="pubmed">35118687</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias S., Harper C., Vrbicky K., Walsh S.R., Essink B., Brosz A., McGhee N., Tomassini J.E., Chen X., Chang Y., et al. A Bivalent Omicron-Containing Booster Vaccine against COVID-19. N. Engl. J. Med. 2022;387:1279–1291. doi: 10.1056/NEJMoa2208343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2208343</ArticleId><ArticleId IdType="pmc">PMC9511634</ArticleId><ArticleId IdType="pubmed">36112399</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J., Kurhade C., Patel S., Kitchin N., Tompkins K., Cutler M., Cooper D., Yang Q., Cai H., Muik A., et al. Improved Neutralization of Micron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine. BioRxiv. 2022 doi: 10.1101/2022.11.17.516898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.11.17.516898</ArticleId><ArticleId IdType="pmc">PMC9891359</ArticleId><ArticleId IdType="pubmed">36734885</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblum H.G. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines—United States, October 2022. MMWR Morb. Mortal. Wkly. Rep. 2022;71:1436–1441. doi: 10.15585/mmwr.mm7145a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7145a2</ArticleId><ArticleId IdType="pmc">PMC9707353</ArticleId><ArticleId IdType="pubmed">36355612</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim L., Garg S., O’Halloran A., Whitaker M., Pham H., Anderson E.J., Armistead I., Bennett N.M., Billing L., Como-Sabetti K., et al. Risk Factors for Intensive Care Unit Admission and In-Hospital Mortality among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET) Clin. Infect. Dis. 2021;72:e206–e214. doi: 10.1093/cid/ciaa1012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1012</ArticleId><ArticleId IdType="pmc">PMC7454425</ArticleId><ArticleId IdType="pubmed">32674114</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal N., Cao Z., Gundrum J., Sianis J., Safo S. Risk Factors Associated with In-Hospital Mortality in a US National Sample of Patients with COVID-19. JAMA Netw. Open. 2020;3:e2029058. doi: 10.1001/jamanetworkopen.2020.29058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.29058</ArticleId><ArticleId IdType="pmc">PMC7729428</ArticleId><ArticleId IdType="pubmed">33301018</ArticleId></ArticleIdList></Reference><Reference><Citation>Boersma P., Black L.I., Ward B.W. Prevalence of Multiple Chronic Conditions among US Adults, 2018. Prev. Chronic Dis. 2020;17:200130. doi: 10.5888/pcd17.200130.</Citation><ArticleIdList><ArticleId IdType="doi">10.5888/pcd17.200130</ArticleId><ArticleId IdType="pmc">PMC7553211</ArticleId><ArticleId IdType="pubmed">32945769</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopel H., Bogdanov A., Winer-Jones J.P., Adams C., Winer I.H., Bonafede M., Nguyen V.H., Mansi J.A. Comparison of COVID-19 and Influenza-Related Outcomes in the United States during Fall–Winter 2022–2023: A Cross-Sectional Retrospective Study. Diseases. 2024;12:16. doi: 10.3390/diseases12010016.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diseases12010016</ArticleId><ArticleId IdType="pmc">PMC10814040</ArticleId><ArticleId IdType="pubmed">38248367</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  COVID-NET: COVID-19-Associated Hospitalization Surveillance Network.  [(accessed on 2 September 2023)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/covidnetdashboard/de/powerbi/dashboard.html.</Citation></Reference><Reference><Citation>Kopel H., Nguyen V.H., Boileau C., Bogdanov A., Winer I., Ducruet T., Zeng N., Bonafede M., Esposito D.B., Martin D., et al. Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults. Vaccines. 2023;11:1711. doi: 10.3390/vaccines11111711.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11111711</ArticleId><ArticleId IdType="pmc">PMC10675676</ArticleId><ArticleId IdType="pubmed">38006043</ArticleId></ArticleIdList></Reference><Reference><Citation>Boikos C., McGovern I., Molrine D., Ortiz J.R., Puig-Barberà J., Haag M. Review of Analyses Estimating Relative Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Three Consecutive US Influenza Seasons. Vaccines. 2022;10:896. doi: 10.3390/vaccines10060896.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10060896</ArticleId><ArticleId IdType="pmc">PMC9228909</ArticleId><ArticleId IdType="pubmed">35746504</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen V.H., Boileau C., Bogdanov A., Sredl M., Bonafede M., Ducruet T., Chavers S., Rosen A., Martin D., Buck P., et al. Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and Homologous Boosting in Preventing COVID-19 in Adults in the US. Open Forum Infect. Dis. 2023;10:288. doi: 10.1093/ofid/ofad288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad288</ArticleId><ArticleId IdType="pmc">PMC10368199</ArticleId><ArticleId IdType="pubmed">37496607</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals.  [(accessed on 5 September 2023)]; Available online:  https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html.</Citation></Reference><Reference><Citation>Benavidez G.A., Zahnd W.E., Hung P., Eberth J.M. Chronic Disease Prevalence in the US: Sociodemographic and Geographic Variations by Zip Code Tabulation Area. Prev. Chronic Dis. 2024;21:E14. doi: 10.5888/pcd21.230267.</Citation><ArticleIdList><ArticleId IdType="doi">10.5888/pcd21.230267</ArticleId><ArticleId IdType="pmc">PMC10944638</ArticleId><ArticleId IdType="pubmed">38426538</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulme W.J., Horne E.M.F., Parker E.P.K., Keogh R.H., Williamson E.J., Walker V., Palmer T.M., Curtis H.J., Walker A.J., Andrews C.D., et al. Comparative Effectiveness of BNT162b2 versus mRNA-1273 Covid-19 Vaccine Boosting in England: Matched Cohort Study in OpenSAFELY-TPP. BMJ. 2023;380:e072808. doi: 10.1136/bmj-2022-072808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072808</ArticleId><ArticleId IdType="pmc">PMC10014664</ArticleId><ArticleId IdType="pubmed">36921925</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerman B.A., Gerlovin H., Madenci A.L., Figueroa Muñiz M.J., Wise J.K., Adhikari N., Ferolito B.R., Kurgansky K.E., Gagnon D.R., Cho K., et al. Comparative Effectiveness of Third Doses of mRNA-Based COVID-19 Vaccines in US Veterans. Nat. Microbiol. 2023;8:55–63. doi: 10.1038/s41564-022-01272-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01272-z</ArticleId><ArticleId IdType="pmc">PMC9949349</ArticleId><ArticleId IdType="pubmed">36593297</ArticleId></ArticleIdList></Reference><Reference><Citation>Embi P.J., Levy M.E., Naleway A.L., Patel P., Gaglani M., Natarajan K., Dascomb K., Ong T.C., Klein N.P., Liao I.-C., et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1553–1559. doi: 10.15585/mmwr.mm7044e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7044e3</ArticleId><ArticleId IdType="pmc">PMC8568092</ArticleId><ArticleId IdType="pubmed">34735426</ArticleId></ArticleIdList></Reference><Reference><Citation>Drawz P.E., DeSilva M., Bodurtha P., Vazquez Benitez G., Murray A., Chamberlain A.M., Dudley R.A., Waring S., Kharbanda A.B., Murphy D., et al. Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and SARS-CoV-2-Related Hospitalizations: A Statewide Report from the Minnesota Electronic Health Record Consortium. Clin. Infect. Dis. 2022;75:890–892. doi: 10.1093/cid/ciac110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac110</ArticleId><ArticleId IdType="pmc">PMC8903410</ArticleId><ArticleId IdType="pubmed">35137021</ArticleId></ArticleIdList></Reference><Reference><Citation>Molnár G.A., Vokó Z., Sütő G., Rokszin G., Nagy D., Surján G., Surján O., Nagy P., Kenessey I., Wéber A., et al. Effectiveness of SARS-CoV-2 Primary Vaccines and Boosters in Patients with Type 2 Diabetes Mellitus in Hungary (HUN-VE 4 Study) BMJ Open Diabetes Res. Care. 2024;12:e003777. doi: 10.1136/bmjdrc-2023-003777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjdrc-2023-003777</ArticleId><ArticleId IdType="pmc">PMC10823926</ArticleId><ArticleId IdType="pubmed">38267204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavikondala S., Haeussler K., Wang X., Spellman A., Bausch-Jurken M.T., Sharma P., Amiri M., Krivelyova A., Vats S., Nassim M., et al. Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-Analysis Using GRADE. Infect. Dis. Ther. 2024;13:1419–1438. doi: 10.1007/s40121-024-00987-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-024-00987-2</ArticleId><ArticleId IdType="pmc">PMC11219657</ArticleId><ArticleId IdType="pubmed">38802704</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavrovouniotis I., Fylaktou A., Stagou M., Ouranos K., Lioulios G., Evgenikaki E., Exindari M., Gioula G. Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines. Life. 2023;13:474. doi: 10.3390/life13020474.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life13020474</ArticleId><ArticleId IdType="pmc">PMC9967689</ArticleId><ArticleId IdType="pubmed">36836831</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao S.-Y., Gerber A.N., Zelarney P., Make B., Wechsler M.E. Impaired SARS-CoV-2 mRNA Vaccine Antibody Response in Chronic Medical Conditions: A Real-World Analysis. Chest. 2022;161:1490–1493. doi: 10.1016/j.chest.2021.12.654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.12.654</ArticleId><ArticleId IdType="pmc">PMC8743857</ArticleId><ArticleId IdType="pubmed">35016912</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia X., Dong F., Pyle L., Michels A.W., Yu L., Rewers M. Similar Time Course of Humoral Response to SARS-CoV-2 mRNA Vaccines in People with and without Type 1 Diabetes. Diabetes Technol. Ther. 2023;25:492–496. doi: 10.1089/dia.2023.0016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/dia.2023.0016</ArticleId><ArticleId IdType="pmc">PMC10398735</ArticleId><ArticleId IdType="pubmed">36989496</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuhann J.M., Stemler J., Carcas A.J., Frías-Iniesta J., Akova M., Bethe U., Heringer S., Salmanton-García J., Tischmann L., Zarrouk M., et al. Immunogenicity and Reactogenicity of a First Booster with BNT162b2 or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1) Vaccine. 2023;41:7166–7175. doi: 10.1016/j.vaccine.2023.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.10.029</ArticleId><ArticleId IdType="pubmed">37919141</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark A., Jit M., Warren-Gash C., Guthrie B., Wang H.H.X., Mercer S.W., Sanderson C., McKee M., Troeger C., Ong K.L., et al. Global, Regional, and National Estimates of the Population at Increased Risk of Severe COVID-19 Due to Underlying Health Conditions in 2020: A Modelling Study. Lancet Glob. Health. 2020;8:e1003–e1017. doi: 10.1016/S2214-109X(20)30264-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(20)30264-3</ArticleId><ArticleId IdType="pmc">PMC7295519</ArticleId><ArticleId IdType="pubmed">32553130</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried M.W., Crawford J.M., Mospan A.R., Watkins S.E., Munoz B., Zink R.C., Elliott S., Burleson K., Landis C., Reddy K.R., et al. Patient Characteristics and Outcomes of 11 721 Patients with Coronavirus Disease 2019 (COVID-19) Hospitalized across the United States. Clin. Infect. Dis. 2021;72:e558–e565. doi: 10.1093/cid/ciaa1268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1268</ArticleId><ArticleId IdType="pmc">PMC7499515</ArticleId><ArticleId IdType="pubmed">32856034</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison S.L., Fazio-Eynullayeva E., Lane D.A., Underhill P., Lip G.Y.H. Comorbidities Associated with Mortality in 31,461 Adults with COVID-19 in the United States: A Federated Electronic Medical Record Analysis. PLoS Med. 2020;17:e1003321. doi: 10.1371/journal.pmed.1003321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003321</ArticleId><ArticleId IdType="pmc">PMC7482833</ArticleId><ArticleId IdType="pubmed">32911500</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo Marin B., Aghagoli G., Lavine K., Yang L., Siff E.J., Chiang S.S., Salazar-Mather T.P., Dumenco L., Savaria M.C., Aung S.N., et al. Predictors of COVID-19 Severity: A Literature Review. Rev. Med. Virol. 2021;31:1–10. doi: 10.1002/rmv.2146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2146</ArticleId><ArticleId IdType="pmc">PMC7855377</ArticleId><ArticleId IdType="pubmed">32845042</ArticleId></ArticleIdList></Reference><Reference><Citation>Kompaniyets L. Underlying Medical Conditions and Severe Illness among 540,667 Adults Hospitalized with COVID-19, March 2020–March 2021. Prev. Chronic Dis. 2021;18:210123. doi: 10.5888/pcd18.210123.</Citation><ArticleIdList><ArticleId IdType="doi">10.5888/pcd18.210123</ArticleId><ArticleId IdType="pmc">PMC8269743</ArticleId><ArticleId IdType="pubmed">34197283</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha S.S., Kompaniyets L., Grosse S.D., Harris A.M., Baggs J., Sircar K., Gundlapalli A.V. Estimation of Coronavirus Disease 2019 Hospitalization Costs from a Large Electronic Administrative Discharge Database, March 2020–July 2021. Open Forum Infect. Dis. 2021;8:ofab561. doi: 10.1093/ofid/ofab561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab561</ArticleId><ArticleId IdType="pmc">PMC8686820</ArticleId><ArticleId IdType="pubmed">34938822</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott A., Ansari W., Khan F., Chambers R., Benigno M., Di Fusco M., McGrath L., Malhotra D., Draica F., Nguyen J., et al. Substantial Health and Economic Burden of COVID-19 during the Year after Acute Illness among US Adults at High Risk of Severe COVID-19. BMC Med. 2024;22:46. doi: 10.1186/s12916-023-03234-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-023-03234-6</ArticleId><ArticleId IdType="pmc">PMC10836000</ArticleId><ArticleId IdType="pubmed">38303065</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>